首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth
【24h】

Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth

机译:人参来源的纳米粒子改变巨噬细胞极化,抑制黑色素瘤的生长

获取原文
           

摘要

Abstract BackgroundIt is unclear whether plant-derived extracellular vesicles (EVs) can mediate interspecies communication with mammalian cells. Tumor-associated macrophages (TAMs) display a continuum of different polarization states between tumoricidal M1 phenotype and tumor-supportive M2 phenotypes, with a lower M1/M2 ratio correlating with tumor growth, angiogenesis and invasion. We investigated whether EVs from ginseng can alter M2-like polarization both in vitro and in vivo to promote cancer immunotherapy.MethodsA novel EVs-liked ginseng-derived nanoparticles (GDNPs) were isolated and characterized from Panax ginseng C. A. Mey. Using GDNPs as an immunopotentiator for altering M2 polarized macrophages, we analyzed associated surface markers, genes and cytokines of macrophages treated with GDNPs. Mice bearing B16F10 melanoma were treated with GDNPs therapy. Tumor growth were assessed, and TAM populations were evaluated by FACS and IF.ResultsGDNPs significantly promoted the polarization of M2 to M1 phenotype and produce total reactive oxygen species, resulting in increasing apoptosis of mouse melanoma cells. GDNP-induced M1 polarization was found to depend upon Toll-like receptor (TLR)-4 and myeloid differentiation antigen 88 (MyD88)-mediated signaling. Moreover, ceramide lipids and proteins of GDNPs may play an important role in macrophage polarization via TLR4 activation. We found that GDNPs treatment significantly suppressed melanoma growth in tumor-bearing mice with increased presence of M1 macrophages detected in the tumor tissue.ConclusionsGDNPs can alter M2 polarization both in vitro and in vivo, which contributes to an antitumor response. The polarization of macrophages induced by GDNPs is largely dependent on TLR4 and MyD88 signalling. GDNPs as an immunomodulator participate in mammalian immune response and may represent a new class of nano-drugs in cancer immunotherapy.
机译:摘要背景尚不清楚植物源性细胞外囊泡(EVs)是否能介导与哺乳动物细胞的种间通讯。肿瘤相关的巨噬细胞(TAM)在杀肿瘤的M1表型和支持肿瘤的M2表型之间表现出不同极化状态的连续性,而较低的M1 / M2比值则与肿瘤的生长,血管生成和侵袭相关。我们研究了人参EV是否可以在体内和体外改变M2样极化以促进癌症免疫治疗。方法从人参C. A. Mey分离并表征了一种新型的EV样人参衍生纳米颗粒(GDNP)。使用GDNPs作为改变M2极化巨噬细胞的免疫增强剂,我们分析了用GDNPs处理的巨噬细胞的相关表面标记,基因和细胞因子。用GDNPs治疗携带B16F10黑素瘤的小鼠。结果表明,GDNPs显着促进了M2向M1的极化,并产生了总的活性氧,导致小鼠黑素瘤细胞凋亡增加。发现GDNP诱导的M1极化取决于Toll样受体(TLR)-4和髓样分化抗原88(MyD88)介导的信号传导。此外,神经酰胺脂质和GDNPs蛋白可能通过TLR4激活在巨噬细胞极化中起重要作用。我们发现GDNPs治疗可以显着抑制荷瘤小鼠黑色素瘤的生长,并在肿瘤组织中检测到M1巨噬细胞的存在增加。结论GDNPs可以在体内和体外改变M2极化,从而有助于抗肿瘤反应。 GDNPs诱导巨噬细胞的极化很大程度上取决于TLR4和MyD88信号。 GDNPs作为一种免疫调节剂参与哺乳动物的免疫反应,并可能代表癌症免疫疗法中一类新的纳米药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号